Aldo-keto reductase 1C3 (AKR1C3) is an important human enzyme that participates in the reduction of steroids and prostaglandins, which leads to proliferative signaling. AKR1C3 is frequently upregulated in various cancers, and this enzyme has been suggested as a therapeutic target for the treatment of these pathological conditions. The fact that the isoquinoline alkaloid stylopine has been identified as a potent AKR1C3 inhibitor has prompted us to screen a library of diverse types of Amaryllidaceae alkaloids, which biogenetically are isoquinoline alkaloids, on a recombinant form of AKR1C3. From the tested compounds, only tazettine showed moderate AKR1C3 inhibitory potency with an IC 50 value of 15.8 ± 1.2 µM. Tazettine is a common Amaryllidaceae alkaloid, which could be used as a model substance for the further development of either analogues or related compounds with better inhibition potency.
Plants of the Amaryllidaceae family are known for producing an exclusive group of alkaloids, named Amaryllidaceae alkaloids, which are of great interest due to their wide range of biological activities, including antiviral, antimalarial, anticancer and anticholinesteratic [1, 2] . The medical properties of these plants were already known in the fourth century B.C., when Hippocrates of Cos used oil from the daffodil, Narcissus poeticus L., for the treatment of uterine tumors. Some species of this family contain galanthamine, a long-acting, selective, reversible and competitive acetylcholinesterase inhibitor, which has been approved by the Food and Drug Administration for the treatment of mild to moderate Alzheimer's disease under the commercial name Reminyl© (galanthamine hydrobromide). Many Amaryllidaceae alkaloids have been reported to exhibit promising antitumor properties [3a,b] . Those that are cytotoxic at micromolar concentrations include lycorine [3c], narciclasine [3d], pancratistatin [4a] and haemanthamine [2a,4b] .
Human enzyme AKR1C3, also known as 17β-hydroxysteroid dehydrogenase type 5, is a member of the aldo-keto reductase protein superfamily. It catalyzes the reduction of carbonyl groups of several steroids and prostaglandins, which leads to pre-receptor regulation of their action and proliferative signaling. AKR1C3 is involved in the development of several types of hormone-dependent {e.g. breast and castration resistant prostate cancer (CRCP)} and hormone-independent cancers [4c,d]. AKR1C3 is overexpressed in prostate tumors from CRCP patients [5, 6] . Reduction of AKR1C3 activity significantly decreases the level of testosterone, 5α-dihydroxytestosterone, and androgen dependent gene expression e.g. prostate specific antigen. In vivo inhibition of AKR1C3 leads to reduction in growth of xenograft models of CRCP [6, 7] . These research findings have made AKR1C3 a promising target for prostate cancers.
Twenty-eight Amaryllidaceae alkaloids, belonging to seven structural types, have been screened for their potency in inhibiting a recombinant form of AKR1C3. The tested alkaloids belong to (belladine); haemanthamine-(haemanthamine, haemanthidine, hamayne, epimaritidine); crinine-(ambelline, 11-Oacetylambelline, crinine, undulatine, buphanamine, buphanidrine, buphanisine, 1-O-acetylbulbisine), galanthamine-(galanthamine, chlidanthine), lycorine-(caranine, acetylcaranine, lycorine, 1-Oacetyllycorine, galanthine, 9-O-demethylgalanthine), homolycorine-(homolycorine, masonine, tetrahydromasonine, lycorenine, oduline, hippeastrine) and tazettine-structural types (tazettine) (Figure 1 , Supplementary Material). Of the tested alkaloids, only tazettine showed moderate inhibitory potency (IC 50 = 15.8 ± 1.2 µM) compared with the known AKR1C3 inhibitor, indomethacin (IC 50 = 3.7 µM) [8] ; eleven alkaloids showed weak inhibitory potency and the others were considered as inactive (Figure 1 ). Although tazettine has a lower inhibitory potency than those of known inhibitors (e.g. indomethacin and its analogues, and baccharin), next to another alkaloid stylopine, tazettine is the second alkaloid of interest since it can be used as a lead structure in the development of more potent AKR1C3 inhibitors. The advantage of tazettine is its good availability from natural sources, as it is one of the most abundant alkaloids within the family Amaryllidaceae.
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Experimental
Amaryllidaceae alkaloids: All tested alkaloids have been previously isolated in the laboratory of the Department of Pharmaceutical Botany from Zephyranthes robusta [9a,b] , Chlidanthus fragrans [2a, 9c] , Nerine bowdenii [10] , and Narcissus poeticus cv. Brackenhurst [11a] . The purity (≥ 95 %) of each isolated compound was confirmed by NMR spectroscopy. A stock solution (10 mM) of each alkaloid was prepared in DMSO.
Preparation of recombinant form of AKR1C3:
A recombinant form of human AKR1C3 was prepared in an Escherichia coli expression system and purified to homogeneity, as described previously [11b].
AKR1C3-inhibitory potency assay of Amaryllidaceae alkaloids:
Incubation mixtures, which contained 1.5 µg of pure recombinant AKR1C3, an NADPH-generation system (13 mM NADP+, 96 mM glucose-6-phosphate, 3.5 U glucose-6-phosphate dehydrogenase, 50 mM MgCl 2 ), either 20 µM (for screening purposes) or 4-100 µM (for IC 50 determination) of test alkaloid, and 0.1 M Na-phosphate buffer, pH 7.4, were incubated for 10 min on ice and subsequently pre-incubated for 5 min at 37
• C. The enzymatic reaction was initiated by the addition of Adion in a final concentration of 12 µM. The reaction mixture (100 µL) was incubated at 37
• C for 30 min and then stopped by the addition of 40 µL of 25% NH 4 OH and by cooling to 0
• C. After 10 min on ice, testosterone was extracted with 1 mL of ethyl acetate by shaking for 15 min. Each sample was then centrifuged for 2 min at 13,000 rpm. The organic phases were transferred to new Eppendorf microtubes and evaporated to dryness under vacuum at 30
• C. Control samples of identical composition containing only DMSO without test alkaloids were prepared in an identical manner. A similar procedure to that used for the tested substances was employed for the model inhibitor of AKR1C3, indomethacin. Sample residues were dissolved in 300 µL of mobile phase and subjected to HPLC analysis. The formed metabolite, testosterone, was determined using an HPLC Agilent 1100 Series system (Santa Clara, CA, USA), which was equipped with a BDS Hypersil C18 chromatography column (250 × 4.6 mm, 5 µm) and a BDS 10 × 4 mm i.d. 5 µm guard column (Thermo Electron Corporation, UK). A mobile phase consisting of methanol:water 70:30, v/v, at a flow rate of 0.6 mL/min was used; detection was performed using a diode array detector at 240 nm.
